Last reviewed · How we verify
Genotonorm (Somatropin)
Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.
Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature associated with Turner syndrome.
At a glance
| Generic name | Genotonorm (Somatropin) |
|---|---|
| Sponsor | Pfizer |
| Drug class | Recombinant human growth hormone |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Somatropin mimics endogenous growth hormone by activating GH receptors on target tissues, promoting linear growth in children, increasing lean body mass, and enhancing metabolic function. It stimulates insulin-like growth factor 1 (IGF-1) production, which mediates many of growth hormone's anabolic and metabolic effects.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature associated with Turner syndrome
- Chronic kidney disease-related growth failure
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Fluid retention
- Carpal tunnel syndrome
- Arthralgia
Key clinical trials
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (PHASE3)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (PHASE1, PHASE2)
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance (PHASE2)
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genotonorm (Somatropin) CI brief — competitive landscape report
- Genotonorm (Somatropin) updates RSS · CI watch RSS
- Pfizer portfolio CI